文献速递肿瘤 PET/CT

根治性前列腺切除术后前列腺癌局部复发在68Ga-PSMA-11-PET/CT与PET/MRI中易被遗漏:与同步PET/MRI整合的多参数MRI比较

Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2016-12-17

119例根治性前列腺切除术后生化复发患者行68Ga-PSMA-11-PET/CT低剂量(注射后1小时)和PET/MRI(注射后2-3小时,含前列腺床多参数MRI方案),比较两种方法对局部复发的检测。18/119例(15.1%)经PET/MRI的mpMRI诊断局部复发,但仅9例在PET/CT和PET/MRI中PET阳性,差异有统计学意义(p=0.004)。PET对局部复发的检测受病灶与膀胱邻近程度显著影响(p=0.028),病灶大小不影响PET可检测性(p=0.84)。

要点

  • 18/119例(15.1%)经mpMRI诊断局部复发,仅9例PET阳性,差异显著(p=0.004)。
  • PET检测局部复发受病灶与膀胱邻近程度显著影响(p=0.028)。
  • 局部复发大小不影响PET可检测性(p=0.84),平均长轴1.7±0.69 cm、短轴1.2±0.46 cm。

核心结论

  • 本研究显示,对于前列腺癌局部复发患者,68Ga-PSMA-11-PET/MRI相较于68Ga-PSMA-11-PET/CT低剂量能获得互补的诊断信息,具有额外价值。

研究设计与样本

  • 119例既往根治性前列腺切除术后生化复发患者,均行68Ga-PSMA-11-PET/CT低剂量(注射后1小时)和68Ga-PSMA-11-PET/MRI(注射后2-3小时,含前列腺床多参数MRI方案),比较限于腹部并聚焦局部复发(McNemar检验)。
  • 在轴位T2w-TSE上测量膀胱-局部复发距离和复发灶大小,采用逻辑回归分析这些变量对68Ga-PSMA-11-PET可检测性的影响,并对局部复发进行标准化摄取值(SUVmean)定量。

主要发现

  • 93/119例患者至少有一项病理发现。
  • 18/119例患者(15.1%)经PET/MRI的mpMRI诊断局部复发,但仅9例在PET/CT和PET/MRI中PET阳性,该不匹配有统计学意义(p=0.004)。
  • PET成分检测局部复发显著受病灶与膀胱邻近程度影响(p=0.028)。
  • 局部复发大小不影响PET可检测性(p=0.84),平均长轴1.7±0.69 cm、短轴1.2±0.46 cm。
  • 9例男性局部复发的SUVmean为8.7±3.7(PET/CT)和7.0±4.2(PET/MRI),其余9例因被膀胱遮蔽而无法定量。

关键数值与推荐

  • 局部复发PET摄取模式分为三型:1型与膀胱分离;2型与膀胱融合;3型被膀胱遮蔽。
  • 18/119例(15.1%)经mpMRI诊断局部复发,其中仅9例PET阳性(p=0.004)。
  • 局部复发平均大小长轴1.7±0.69 cm、短轴1.2±0.46 cm(p=0.84)。
  • 9例可定量者SUVmean为8.7±3.7(PET/CT)和7.0±4.2(PET/MRI)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The positron emission tomography (PET) tracer 68Ga-PSMA-11, targeting the prostate-specific membrane antigen (PSMA), is rapidly excreted into the urinary tract. This leads to significant radioactivity in the bladder, which may limit the PET-detection of local recurrence (LR) of prostate cancer (PC) after radical prostatectomy (RP), developing in close proximity to the bladder. Here, we analyze if there is additional value of multi-parametric magnetic resonance imaging (mpMRI) compared to the 68Ga-PSMA-11-PET-component of PET/CT or PET/MRI to detect LR. METHODS: One hundred and nineteen patients with biochemical recurrence after prior RP underwent both hybrid 68Ga-PSMA-11-PET/CTlow-dose (1 h p.i.) and -PET/MRI (2-3 h p.i.) including a mpMRI protocol of the prostatic bed. The comparison of both methods was restricted to the abdomen with focus on LR (McNemar). Bladder-LR distance and recurrence size were measured in axial T2w-TSE. A logistic regression was performed to determine the influence of these variables on detectability in 68Ga-PSMA-11-PET. Standardized-uptake-value (SUVmean) quantification of LR was performed. RESULTS: There were 93/119 patients that had at least one pathologic finding. In addition, 18/119 Patients (15.1%) were diagnosed with a LR in mpMRI of PET/MRI but only nine were PET-positive in PET/CT and PET/MRI. This mismatch was statistically significant (p = 0.004). Detection of LR using the PET-component was significantly influenced by proximity to the bladder (p = 0.028). The PET-pattern of LR-uptake was classified into three types (1): separated from bladder; (2): fuses with bladder, and (3): obliterated by bladder). The size of LRs did not affect PET-detectability (p = 0.84), mean size was 1.7 ± 0.69 cm long axis, 1.2 ± 0.46 cm short-axis. SUVmean in nine men was 8.7 ± 3.7 (PET/CT) and 7.0 ± 4.2 (PET/MRI) but could not be quantified in the remaining nine cases (obliterated by bladder). CONCLUSION: The present study demonstrates additional value of hybrid 68Ga-PSMA-11-PET/MRI by gaining complementary diagnostic information compared to the 68Ga-PSMA-11-PET/CTlow-dose for patients with LR of PC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2016. PMID: 27988802. doi:10.1007/s00259-016-3594-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。